Federico Piacentini - Concepedia

Author

Federico Piacentini

University of Modena and Reggio Emilia ORCID

Also Known As

Dieci, M.V., F Piacentini, F. Piacentini, Federico Piacentini, Giampaolo Bianchini, Piacentini, F.

249

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

University of Modena and Reggio Emilia Istituti di Ricovero e Cura a Carattere Scientifico Istituto Oncologico Veneto University of Padua University of Parma

About

Federico Piacentini is an author at University of Modena and Reggio Emilia specializing in oncology, breast cancer, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	19	1.2K
2	Health Sciences	5	5	389
3	Engineering	1	1	17
4	Nursing	1	1	72
5	Public Health	1	1	90

Federico Piacentini

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study Valentina Guarneri, Antonio Frassoldati, Alberto Bottini, Journal of Clinical Oncology	2012	366
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis Maria Vittoria Dieci, Elena Barbieri, Federico Piacentini, Annals of Oncology Breast OncologyTumor HeterogeneityReceptor StatusMedicinePathology	2012	189
Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management Valentina Guarneri, Simona Giovannelli, Guido Ficarra, The Oncologist	2008	152
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study Pierfranco Conté, Antonio Frassoldati, Giancarlo Bisagni, Annals of Oncology	2018	152
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial Maria Vittoria Dieci, Aleix Prat, Enrico Tagliafico, Annals of Oncology Breast OncologyPam50 SubtypesMedicineImmunologyImmune Modulation	2016	149
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients Valentina Guarneri, Maria Vittoria Dieci, Elena Barbieri, Annals of Oncology Breast OncologyNeoadjuvant TherapyMedicinePathologyHer2 Positivity	2013	140
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial Javier Cortés, Véronique Dièras, Jungsil Ro, The Lancet Oncology Breast OncologyOncologyHealth SciencesLux-breast 3Clinical Trials	2015	126
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer Maria Vittoria Dieci, Pierfranco Conté, Giancarlo Bisagni, Annals of Oncology	2019	94
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era Angela Toss, Chrystel Isca, Marta Venturelli, ESMO Open Breast Cancer StageBreast OncologyCovid EraTwo-month StopCancer Detection	2021	90
Immune characterization of breast cancer metastases: prognostic implications Maria Vittoria Dieci, Vassilena Tsvetkova, Enrico Orvieto, Breast Cancer Research	2018	85

Page 1